Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Luveltamab Tazevibulin
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Sutro Biopharma
Deal Size : $385.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Tasly will pursue the clinical development, regulatory approval, and commercialization of STRO-002 in Greater China for ovarian and endometrial cancers.
Product Name : STRO-002
Product Type : Antibody-drug Conjugate
Upfront Cash : $40.0 million
December 27, 2021
Lead Product(s) : Luveltamab Tazevibulin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Sutro Biopharma
Deal Size : $385.0 million
Deal Type : Licensing Agreement
Reset All
